secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001628280-24-021115
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q1 2024 revenue $10.0M, net loss $40.6M; pipeline metrics grow
------------------------------------------------------------------------

- Revenue of $10.0M ($9.8M research fees, $0.2M licensing) down 18% from $12.2M in Q1 2023.
- Net loss of $40.6M ($0.14 per share) compared to net loss of $40.1M in Q1 2023.
- R&D expenses fell to $39.3M from $52.6M; cash & securities $725.3M plus $240M non-dilutive funding.
- Cumulative partner-initiated program starts 90 (up 20% YoY) and molecules in clinic 13 (up 44% YoY).
- Announced collaborations with Biogen for neurological antibodies and with Viking/ArrowMark to launch biotechs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000162828024021115/0001628280-24-021115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000162828024021115/abcl-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer